In a critical advance in targeting BTN3A1 in the setting of cancer, Imcheck Therapeutics has developed a BTN3A-specific antibody, ICT01, a humanized version of clone 7.2 that recognizes an epitope within BTN3A1 which overlaps with clone 20.1. This evidence concerns the gene BTN3A1 and cancer.